Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00641056 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 467
- Enrollment target
NCT00641056 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 467 participants.
The verdict
NCT00641056, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 467 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effects of 2.0 mg exenatide once weekly and insulin glargine, titrated to glucose targets using the algorithm described by Yki- Järvinen et al.(2007), with respect to glycemic improvements, body weight, fasting lipids, safety, and tolerability.
Interventions
- DRUG Insulin Glargine
- DRUG Exenatide Once Weekly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00641056
The ClinicalTrials.gov registry entry for NCT00641056 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 467 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin Glargine is the first listed.
NCT00641056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00641056 about?
NCT00641056 is a clinical study titled "Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)". The purpose of this study is to compare the effects of 2.0 mg exenatide once weekly and insulin glargine, titrated to glucose targets using the algorithm described by Yki- Järvinen et al.(2007), with respect to glycemic improvements, body weight, fasting lipids, safety, and tolerability.
What is the current status of trial NCT00641056?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 467 participants. The study started on 2008-04. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00641056?
The interventions under investigation include: Insulin Glargine (DRUG), Exenatide Once Weekly (DRUG).
Who is sponsoring clinical trial NCT00641056?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.